The Pharma Letter5 小时
AstraZeneca plans $570 million investment in Canada
Spreading its geographic wings further, in the face of ongoing difficulties in China, UK pharma major AstraZeneca has ...
The Pharma Letter5 小时
FDA delays PDUFA action date for elamipretide
US clinical-stage drug developer Stealth BioTherapeutics announced that the US Food and Drug Administration (FDA) has ...
The Pharma Letter6 小时
Vigil moves into Phase II with Alzheimer's pill
Vigil Neuroscience advances VG-3927, a small molecule TREM2 agonist, into Phase II Alzheimer’s trials in Q3 2025 following ...
The Pharma Letter7 小时
RPD designation for Nippon Shinyaku’s DMD candidate
The US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to NS-051/NCNP-04, which is ...
The Pharma Letter7 小时
Genmab names US general manager
Danish biotech Genmab (CPH: GMAB) today announced it has named Leslie Amendola senior vice president and general manager of ...
The Pharma Letter3 小时
BRIEF—Andembry approved to prevent angioedema attacks by MHRA
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved garadacimab (brand name Andembry) for patients aged 12 years and older with hereditary angioedema (HAE) to ...
The Pharma Letter6 小时
US states squeeze Sacklers with upsized $7.4 billion settlement
Purdue Pharma and the Sackler family reach a $7.4 billion settlement over their role in the US opioid crisis. The deal, increasing the previous offer by $1.4 billion, ends Sackler control of Purdue ...